61439-59-6

Basic information

• Product Name: 2-(4-BENZYLOXYPHENYL)ETHANOL
• Synonyms: 4-BENZYLOXYPHENYLETHAN-2-OL;4-BENZYLOXYPHENYLETHYL ALCOHOL;2-(4-BENZYLOXYPHENYL)ETHANOL;p-(benzyloxy)phenethyl alcohol;4-Benzyloxyphenethyl Alcohol;2-(4-Benzyloxyphenyl)ethanol, 98+%;-(p-Benzyloxyphenyl)ethyl Alcohol;2-(p-Benzyloxyphenyl)ethanol
• CAS NO: 61439-59-6
• Molecular Formula: C₁₅H₁₆O₂
• Molecular Weight: 228.29
• EINECS: 262-795-2
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Aromatics
• Mol File: 61439-59-6.mol
• Article Data: 53

Chemical Properties

• Melting Point: 85-87°C
• Boiling Point: 379.1 °C at 760 mmHg
• Flash Point: 170.1 °C
• Appearance: white solid
• Density: 1.116 g/cm³
• Vapor Pressure: 2.02E-06mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.93±0.10(Predicted)
• BRN: 2054624
• CAS DataBase Reference: 2-(4-BENZYLOXYPHENYL)ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BENZYLOXYPHENYL)ETHANOL(61439-59-6)
• EPA Substance Registry System: 2-(4-BENZYLOXYPHENYL)ETHANOL(61439-59-6)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 61439-59-6(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Betaxolol Impurity

InChI:InChI=1/C15H16O2/c16-11-10-13-6-8-15(9-7-13)17-12-14-4-2-1-3-5-14/h1-9,16H,10-12H2

Upstream product

• 501-94-0 p-hydroxyphenethyl alcohol 
• 100-44-7 benzyl chloride 
• 7021-11-6 4-(4-hydroxyphenyl)butanoic acid 
• 36438-64-9 p-benzyloxystyrene 
• 100-39-0 benzyl bromide 
• 63365-56-0 1-(4-(benzyloxy)phenyl)-2-chloroethanone 
• 6305-04-0 p-hydroxyphenacyl chloride 
• 108-95-2 phenol 
• 72734-74-8 (p-benzyloxy-phenyl)-ethyleneoxide 
• 75-21-8 oxirane 
• 7700-27-8 4-chlorophenyl benzyl ether 
• 106-48-9 4-chloro-phenol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 61439-60-9 1-benzyloxy-4-(2-methanesulfonyloxyethyl)benzene 
• 63659-15-4 1-benzyloxy-4-(2-cyclopropylmethoxyethyl)benzene 
• 63659-31-4 4-<(cyclobutylmethoxy)ethyl>-1-(phenylmethoxy)benzene 
• 71488-47-6 2-(p-benzyloxyphenyl)-ethyl chloride 
• 163930-30-1 2-<4-(Benzyloxy)phenyl>ethyl iodide 
• 194658-59-8 Tridecanoic acid 2-(4-benzyloxy-phenyl)-ethyl ester 
• 40167-10-0 2-[4-(benzyloxy)phenyl]acetaldehyde 
• 474844-11-6 2-amino-6-[2-(4-benzyloxyphenyl)ethyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 916458-79-2 2-(4-benzyloxyphenyl)ethyl-(2,3,4,6-tetra-O-acetyl)-β-D-glucopyranoside 
• 959786-30-2 d3-1-benzyloxy-4-(2-methoxy-ethyl)-benzene 
• 1224851-60-8 C₂₄H₂₂O₅ 
• 890042-60-1 1-benzyloxy-4-[2-(3-chloro-propoxy)-ethyl]-benzene 
• 1327337-35-8 1-(benzyloxy)-4-(2-octyloxyethyl)benzene 

Relevant articles and documents

A new multifunctional hydroxytyrosol-fenofibrate with antidiabetic, antihyperlipidemic, antioxidant and antiinflammatory action

Dyslipidemia, oxidative stress and inflammation are major risky factors involved in the pathophysiology of type 2 diabetes mellitus and atherosclerosis. Multifunctional intervene is more meaningful. The aim of this study was to evaluate the multifunctional effects of two new compounds, combination of fenofibric acid (FA) with tyrosol (T) or hydroxytyrosol (HT). Compared with fenofibrate (FF), FF-HT exhibited excellent antioxidant capacities in vitro and much improved hypolipidemia, reducing plasma triglyceride (TG), total cholesterol (TC), and malonaldehyde (MDA) by 76%, 54%, and 28%, while FF-T decreased the plasma parameters by 16%, 10%, and 20% in hyperlipidemic mice induced by Triton WR 1339. Furthermore, compound FF-HT exhibited significant antihyperglycemic, antihyperlipidemic, antioxidant and anti-inflammatory activities as well as attenuating hepatotoxicity in a type 2 diabetes experimental mouse model. The histological findings showed that FF-HT suppressed the development of hepatic lipid accumulation and ameliorated the damage in hepatic and pancreatic tissues compared to model mice. This study indicates for the first time that reasonable optimized drug design produce a compound entity which is conducive to the prevention of type 2 diabetes mellitus and its complications.

Preparation method of 2-(4-benzyloxyphenyl)ethanol

The invention provides a preparation method of 2-(4-benzyloxyphenyl)ethanol. The preparation method comprises the following steps: 1) subjecting phenol to reacting with chloroacetyl chloride under the catalysis of aluminum trichloride to obtain a compound as shown in a formula II; 2) subjecting the compound as shown in the formula II to reacting with benzyl halide under an alkaline condition to obtain a compound as shown in a formula III, wherein the benzyl halide is one selected from benzyl bromide and benzyl chloride; 3) performing reduction treatment on the compound as shown in the formula III, and adjusting a reaction system to be an alkaline system to obtain a compound as shown in a formula IV; and 4) under the action of a catalyst, reducing the compound as shown in the formula IV under a hydrogen condition to obtain the 2-(4-benzyloxyphenyl)ethanol as shown in the formula I. The preparation method has the advantages of low cost, mild reaction conditions, safety in operation and less three-waste pollution, and is beneficial to being applied to industrial production.

Butenolide derivative as well as preparation method and application thereof

The invention discloses a butenolide compound as well as a preparation method and an application thereof. The butenolide derivative has the inhibitory activity of protein tyrosine phosphatase 1B (PTP1B), improves insulin resistance of HepG2 cells, generates a remarkable hypoglycemic effect and can be used for preparing a medicine for treating diabetes mellitus.